Sudarshan Pharma Industries Ltd strategy deck summary

Strategy deck of 14 Aug 2025, summarised by AI from the filing.

Sudarshan Pharma reported FY25 revenue ₹505.0 cr (+9.0%) and PAT ₹16.0 cr (+39.3%), and targets export revenue of at least ₹100 cr in FY25-26.

Key takeaways

1. FY25 revenue FY25 revenue from operations ₹505.0 cr (FY24: ₹463.5 cr, +9.0%); H2FY25 revenue ₹277.3 cr (H2FY24: ₹231.7 cr, +19.6%).
2. Margin improvement FY25 EBITDA margin 7.9% (FY24: 4.9%); H2FY25 EBITDA margin 8.4% (H2FY24: 6.2%).
3. Growth driver The company is focusing on increasing exports and manufacturing sales and maximizing profit margin on resale of API in local markets.

Original filing on BSE

Sudarshan Pharma Industries Ltd earnings call, investor presentation and press release summaries

• Q4 FY25: Results deck (2 May 2025)
• Other events: Strategy deck (18 Aug 2026), Strategy deck (14 Aug 2026), Strategy deck (15 May 2026), Strategy deck (31 Jan 2026), Strategy deck (14 Aug 2025)